which last week said it’s moving forward with its own pill. Roche’s experimental capsule, being developed to treat both type-2 diabetes and obesity, was found to be well tolerated in the study ...

On Thursday, Roche’s American depositary receipts rose 2.6% to $38.30. The once-daily pill, called CT-996, helps control blood sugar levels and is being developed to treat diabetes and obesity.